Serum levels of soluble intercellular-1 and vascular cell-1 adhesion molecules in chronic hepatitis C and the influence of interferon-α + ribavirin therapy

Romanian Journal of Gastroenterology

Volumn 11, Issue 4, 2002, Pages 277-283

  Dejica, Doru ^a   Grigorescu, Mircea ^a   Dejica, Valeria ^a   Radu, Corina ^a   Neculoiu, Daniela ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Chronic hepatitis C; Serum soluble intercellular and vascular cell adhesion molecule 1; Treatment with interferon + ribavirin

Indexed keywords

ALPHA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; MALE; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROGNOSIS; RIBAVIRIN; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0036931551     PISSN: 12214167     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Cerny A, Mc Hutchison JG, Pasquinelli C et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995; 95: 521-530.
2. Ballardini G, Groff P, Pontisso P et al. Hepatitis C virus (HCV) genotype tissue antigens, pathogenesis of hepatocellular expresion of HLA-A, B, C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C. J Clin Invest 1995; 95: 2067-2075.
3. Volpes R, Van den Oord JJ, Desmet VJ. Vascular adhesion molecules in acute and chronic liver inflammation. Hepatology 1992; 15: 269-275.
4. García-Monzón C, Sánchez-Madrid F, Garcia-Buey L et al. Vascular adhesion molecule expression in viral chronic hepatitis: Evidence of neoangiogenesis in portal tracts. Gastroenterology 1995; 108: 231-241.
5. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-512.
6. Adams DH, Mainolfi E, Burra P et al. Detection of circulating intercellular adhesion molecule-1 in chronic liver diseases. Hepatology 1992; 16: 810-814.
7. Zöhrens G, Armbrust T, Pirzer U, Meyer zum Büschenfelde KH, Ramadori G. Intercellular adhesion molecule-1 concentration in sera of patients with acute and chronic liver disease: Relationship to disease activity and cirrhosis. Hepatology 1993; 18: 798-802.
8. Pirisi M, Falleti E, Fabris C et al. Circulating intercellular adhesion molecule-1 (cICAM-1) concentration in liver disease. Relationship with cholestasis and functioning hepatic mass. Am J Clin Pathol 1994; 102: 600-604.
9. Simpson KJ, Harrison DJ, Hayes PC. Serum and tissue vascular adhesion molecules in hepatitis C infection. Gut 1994; 35 (Suppl 5), S68.
10. Nouri-Aria KT, Koskinas J, Tibbs CJ, Portmann BC, Williams R. Serum intercellular adhesion molecule-1 levels in chronic hepatitis C: Association with disease activity and response to interferon α. Gut 1995; 36: 599-603.
11. Marui A, Fukuda Y, Koyama Y et al. Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in liver disease and their changes by treatment with interferon. J Int Med Res 1996; 24: 258-265.
12. Pirisi M, Fabris C, Falleti E et al. Serum soluble vascular - Cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseases. Dis Markers 1996; 13: 11-17.
13. Yang SS, Tsai G, Wu CH, Chen DS. Circulating soluble intercellular adhesion molecule-1 in type C viral hepatitis. Hepatogastroenterology 1996; 43: 575-581.
14. Kaplanski G, Farnarier C, Payan M-J, Bongrand P, Durand J-M. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentration and liver inflammation and fibrosis. Dig Dis Sci 1997; 42: 2277-2284.
15. Bagnasco M, Riccio AM, Sinelli N et al. Serum intercellular adhesion molecule-1 and long-term response to IFN-α2b therapy in chronic hepatitis C. J Interferon Cytokine Res 1998; 18: 963-966.
16. Lo Iacono O, García-Monzón C, Almasio P, García-Buey L, Craxi A, Moreno-Otero R. Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-α. Aliment Pharmacol Ther 1998; 12: 1091-1099.
17. Capra F, De Maria E, Lunardi C et al. Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus. A prognostic marker for response to interferon treatment. J Infect Dis 2000; 181: 425-431.
18. Tortorella C, Sacco R, Orlando P, Salerno MT, Schiraldi O, Antonaci S. sICAM-1, sCD95 and sCD95L levels in chronic liver diseases of different etiology. Immunopharmacol Immunotoxicol 2000; 22: 19-33.
19. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 5: 431-435.
20. Giannini C, Thiers V, Nousbaum JB, Stuyver L, Maertens G, Brechot C. Comparative analysis of two genotyping hepatitis C virus based on genotype-specific primers or probes. J Hepatol 1995; 23: 246-253.
21. Taliani G, Badolato MC, Bozza A et al. HCV infection of peripheral blood mononuclear cells and serum levels of soluble ICAM-1 in patients treated with interferon. Arch Virol 1997; 142: 557-565.
22. Piazzolla G, Tortorella C, Fiore G et al. Immunoresponsiveness in chronic hepatitis C patients: Correlation between tissue and serum findings. Immunopharmacol Immunotoxicol 1998; 20: 337-354.
23. Mosnier JF, Scoazec JY, Marcellin P, Degott C, Benhamou JP, Feldmann G. Expression of cytokine-dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C. Gastroenterology 1994; 107: 1457-1468.
24. Banner BF, Allan C, Savas L, Baker S, Barnard G, Bonkovsky HL. Inflammatory markers in chronic hepatitis C. Virchows Arch 1997; 431: 181-187.
25. Seth R, Raymond FD, Makgoba MW. Circulating ICAM-1 isoforms: Diagnostic prospects for inflammatory and immune disorders. Lancet 1991; 338: 83-84.
26. Bevilacqua MP. Endothelial - Leukocyte adhesion molecules. Annu Rev Immunol 1993; 11: 767-804.
27. Pigott R, Dillon LP, Hemingway IH, Gearing AJH. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatant of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-589.
28. Hu KQ, Yu CH, Vierling JM. Up-regulation of intercellular adhesion molecule 1 transcription by hepatitis B virus X protein. Proc Natl Acad Sci USA 1992; 89: 1141-1145.
29. Sansonno D, Cornacchiulo V, Gatti P, Dammacco F. Circulating levels and liver tissue distribution of intercellular adhesion molecule-1 during α-interferon therapy of hepatitis-C virus-associated chronic active liver disease. Int J Clin Lab Res 1992; 22: 100-105.
30. Sansonno D, Cornacchiulo V, Gatti P, Dammacco F. Circulating levels and liver tissue distribution of intercellular adhesion molecule-1 during α-interferon therapy of hepatitis-C virus-associated chronic active liver disease. Int J Clin Lab Res 1992; 22: 100-105.
31. García-Monzón C, García-Buey L, García-Sánchez AS, Pajares JM, Moreno-Otero R. Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interferon alfa-2b. Gastroenterology 1993; 105: 462-469.
32. Chayama K, Saitoh S, Arase Y et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991; 13: 1040-1043.
33. Ning Q, Brown D, Parado J et al. Ribavirin inhibits viral induced macrophage production of TNF, IL-1, the procoagulant fg12 prothrombinase and preserve Th1 cytokine production but inhibits the Th2 cytokine response. J Immunol 1998; 160: 3487-3493.
34. Di Bisceglie AM. Hepatitis C. Lancet 1998; 351: 351-355.
35. Reichard O, Norkrans G, Frydén A et al. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87.